Abstract
The human microbiome has emerged as a key modulator of host immunity, influencing responses to cancer immunotherapy across various malignancies. This review explores the dynamic interplay between the gut microbiota and immune checkpoint blockade (ICB), discussing mechanisms by which microbial diversity and composition modulate antitumor immunity. We examine clinical studies linking specific bacterial species with treatment efficacy, the impact of antibiotics and probiotics, and the emerging role of fecal microbiota transplantation (FMT) in overcoming resistance to immunotherapy. Challenges in standardizing microbiome-based interventions and the need for personalized microbial strategies are addressed. With a focus on melanoma, lung, and gastrointestinal cancers, this article integrates current evidence and future directions to highlight the translational potential of the microbiome-immunotherapy axis in precision oncology.
Keywords
Introduction
The success of cancer immunotherapy, particularly immune checkpoint blockade (ICB), has transformed the treatment landscape across various malignancies. Despite its clinical promise, variability in patient response and the development of resistance remain key challenges. Recent advances have identified the gut microbiome as a significant determinant of immunotherapy outcomes, positioning it as both a predictive biomarker and a therapeutic target.
Gut Microbiota and Immune Modulation
The intestinal microbiota influences both innate and adaptive immune responses. Commensal microbes modulate the activity of antigen-presenting cells, regulatory T cells, and effector T cells, all key players in tumor immunity. Microbial metabolites such as short-chain fatty acids (SCFAs) enhance T cell priming, while toll-like receptors modulate cytokine production.
Microbiome and Immune Checkpoint Blockade
Several studies show that specific gut microbes enhance the efficacy of ICB therapy. For example, Akkermansia muciniphila and Bifidobacterium longum are associated with better responses. Clinical trials in melanoma and non-small cell lung cancer (NSCLC support these observations).
Impact of Antibiotics, Probiotics, and Diet
Antibiotics can negatively affect immunotherapy by disrupting microbiota. While probiotics are often considered helpful, some may reduce microbiome diversity. Diets rich in fiber promote beneficial bacteria and may enhance ICB response.
Fecal Microbiota Transplantation: A Promising Avenue
Fecal microbiota transplantation (FMT) involves transferring gut microbiota from responders to non-responders. Clinical evidence in melanoma patients shows FMT can restore sensitivity to immunotherapy by reshaping the tumor immune environment.
Challenges and Limitations
Standardization, regulatory oversight, and individual microbiota variability are major challenges in implementing microbiome-based interventions clinically.
Future Directions in Microbiome-based Precision Oncology
The future involves identifying predictive microbiota signatures, using synthetic microbial consortia, and integrating microbiome strategies with other immunotherapies.
Conclusion
The gut microbiome is a critical modulator of cancer immunotherapy. Personalized microbiome-based strategies represent a new horizon in precision oncology.
Footnotes
Declaration of Conflict of Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical Approval
NA.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Patient Consent
NA.
